Skip to main content

Advertisement

SpringerLink
Log in

Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Patients with primary progressive or refractory Hodgkin’s disease (HD) or aggressive non-Hodgkin’s lymphoma (NHL) have a particularly poor prognosis. Here we report the results of autologous tandem transplantation in these patients. Patients aged 18–55 years with primary progressive or refractory relapsed HD and aggressive NHL were included. Patients received high-dose etoposide (2000 mg/m2) followed by peripheral blood stem cell harvest (PBSC). The first high-dose chemotherapy (TMC) consisted of thiotepa (750 mg/m2), mitoxantrone (40 mg/m2), and carboplatin (990 mg/m2). Patients with no change (NC), partial remission (PR), or complete remission (CR) after TMC then received BEAM with carmustine (300 mg/m2), etoposide (1200 mg/m2), cytarabine (1600 mg/m2), and melphalan (140 mg/m2). Patients with bulky disease (>5 cm) or residual lymphoma received involved field radiotherapy. Twenty-five patients were included (HD=10, NHL=15, median age 34 years). Two patients with HD achieved a CR and five patients a PR [response rate (RR) 70%]. Three patients (30%) experienced treatment failure including two deaths due to peritransplant complications. Five patients with aggressive NHL were in CR and two patients in PR (RR 46%). Of the eight patients (56%) with treatment failure, three had progressive disease and five died from peritransplant complications. Freedom from treatment failure (FFTF) and overall survival (OS) for all patients after 12 months was 28% and 40%, respectively. Tandem HDCT followed by autologous stem cell transplantation (ASCT) offers a chance of cure in these poor prognostic patients, but is associated with risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96:1280–1286

    Google Scholar 

  2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  CAS  PubMed  Google Scholar 

  3. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    Google Scholar 

  4. Glossmann JP, Josting A, Diehl V (2002) New treatments for Hodgkin’s disease. Curr Treat Options Oncol 3:283–290

    Google Scholar 

  5. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054

    Google Scholar 

  6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545

    Article  CAS  PubMed  Google Scholar 

  7. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 18:332–339

    Google Scholar 

  8. Vose JM (1998) High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin’s lymphoma. Ann Oncol 9 [Suppl 1]:S1–S3

    Google Scholar 

  9. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429

    CAS  PubMed  Google Scholar 

  10. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 81:1137–1145

    Google Scholar 

  11. Josting A, Katay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD (1998) Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289–295

    Google Scholar 

  12. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340–344

    Google Scholar 

  13. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D et al (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 11:704–711

    Google Scholar 

  14. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA et al (1993) One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351–2361

    Google Scholar 

  15. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens—a Southwest Oncology Group trial. J Clin Oncol 16:48–55

    Google Scholar 

  16. Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M (1997) Single and double autotransplants for relapsing/refractory Hodgkin’s disease: results of two consecutive trials. Bone Marrow Transplant 19:449–454

    Google Scholar 

  17. Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To LB (1991) Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 77:2591–2596

    Google Scholar 

  18. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Google Scholar 

  19. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218

    Google Scholar 

  20. Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman CA Jr, Fisher RI (1994) Autologous bone marrow transplantation in adults with non-Hodgkin’s lymphoma: a Southwest Oncology Group study. Hematol Oncol 12:75–85

    Google Scholar 

  21. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528–534

    Google Scholar 

  22. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin’s disease. Semin Hematol 25:47–50

    Google Scholar 

  23. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:745–752

    Google Scholar 

  24. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 4:767–773

    Google Scholar 

  25. Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD et al (1990) High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 8:527–537

    Google Scholar 

  26. Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Ferme C, Gisselbrecht C (1999) Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 24:747–755

    Google Scholar 

  27. Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA Study Group. Ann Oncol 10:1485–1488

    Google Scholar 

  28. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ et al (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV+/-P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451–456

    Google Scholar 

  29. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P, Bonadonna G (1993) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin’s disease-a 6-year update. Ann Oncol 4:889–891

    Google Scholar 

  30. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690–1695

    Google Scholar 

  31. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291–1296

    Google Scholar 

  32. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342–2350

    Google Scholar 

  33. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20:4022–4031

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany

    Jan-Peter Glossmann, Jan Oliver Staak, Lucia Nogova, Christoph Scheid, Andreas Engert & Andreas Josting

  2. Department of Internal Medicine, Section Hematology/Oncology, University of Lübeck School of Medicine, Lübeck, Germany

    Jens Kisro

  3. Department for Internal Medicine, St. Franziskus Hospital, Mönchen-Gladbach, Germany

    Hans-Edgar Reis

  4. Department of Hematology/Oncology, Carl-Thiem Hospital, Cottbus, Germany

    Norma Peter

  5. German Hodgkin Lymphoma Study Group, Cologne, Germany

    Volker Diehl

Authors
  1. Jan-Peter Glossmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Oliver Staak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucia Nogova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Volker Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christoph Scheid
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jens Kisro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hans-Edgar Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Norma Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andreas Josting
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Josting.

Additional information

J.-P. Glossmann and J. O. Staak have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glossmann, JP., Staak, J.O., Nogova, L. et al. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol 84, 517–525 (2005). https://doi.org/10.1007/s00277-005-1011-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1011-y

Keywords

Search

Navigation